Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy

Epilepsy and Behavior

Volumn 20, Issue 4, 2011, Pages 691-693

  Gavatha, M ^a   Ioannou, I ^a   Papavasiliou, A S ^a  

^a PENTELI CHILDREN S HOSPITAL   (Greece)

Author keywords

Epilepsy; Focal epilepsy; Lacosamide; Pediatric patients; Pharmacoresistant epilepsy; Therapy

Indexed keywords

ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; RUFINAMIDE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOCAL EPILEPSY; HUMAN; INFANT; IRRITABILITY; KETOGENIC DIET; MALE; PANCYTOPENIA; PRESCHOOL CHILD; SCHOOL CHILD; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TREATMENT DURATION; VAGUS NERVE STIMULATION;

ACETAMIDES; ADMINISTRATION, ORAL; ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PEDIATRICS; TREATMENT OUTCOME;

EID: 79954606109     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2011.02.005     Document Type: Article

References (15)

1. Hermann B., Seidenberg M., Jones J. The neurobehavioural comorbidities of epilepsy: can a natural history be developed?. Lancet Neurol 2008, 7:151-160.
2. Sander J.W. The use of anti-epileptic drugs-principles and practice. Epilepsia 2004, 45:28-34.
3. Kwan P., Brodie M. Early identification of refractory epilepsy. N Engl J Med 2000, 342:314-319.
4. Bjornaes H., Stabell K., Henriksen O., Loyning Y. The effects of refractory epilepsy on intellectual functioning in children and adults: a longitudinal study. Seizure 2001, 10:250-259.
5. Aldenkamp A.P., De Krom M., Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia 2003, 44:21-29.
6. Beydoun A., D'Souza J., Hebert D., Doty P. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 2009, 9:33-42.
7. Beyreuther B.K., Freitag J., Heers C., Krebsfanger N., Scharfenecker U., Stohr T. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007, 13:21-42.
8. Ben-Menachem E., Biton V., Jatuzis D., Abou-Khalil B., Doty P., Rudd G.D. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007, 48:1308-1317.
9. Halász P., Kälviäinen R., Mazurkiewicz-Beldzinska M., et al. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009, 50:443-453.
10. Wehner T., Bauer S., Hammer H.M., et al. Six months of post marketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy center in Germany. Epilepsy Behav 2009, 16:423-425.
11. Berg A.T., Shinnar S. Newly diagnosed epilepsy in children: presentation at diagnosis. Epilepsia 1999, 40:445-452.
12. Errington A.C., Coyne L., Stohr T., Selve N., Lees G. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 2006, 50:1016-1029.
13. Kwan P., Arzimanoglou A., Berg A.T., et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010, 51:11069-11077. Erratum: 2010;51:1922. Comment: 2010;51:2360-1.
14. Berg A.T., Berkovic S.F., Brodie M.J., et al. Revised terminology and concepts for organisation of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010, 51:676-685.
15. Sake J.K., Hebert D., Isojärvi J., et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 2010, 24:1055-1068.